Nuclear Medicine Market Is Witnessing Significant Growth Due To Rising Incidence Of Cancer & Cardiovascular Disease Till 2025
The nuclear medicine market is expected to reach USD
13.8 billion by 2024, according to a new report by Grand View Research, Inc.
The burden of chronic diseases such as cancer and cardiac disorders is on rise.
Nuclear medicine products are widely used for diagnosis as well as treatment of
cancerous and cardiovascular disease.
The
increasing prevalence of these disorders poses direct impact on usage of
radiopharmaceutical market. For instance, as per the data published by the
World Health Organization (WHO), the incidences of cancer are anticipated to
increase by 70.0% which is further anticipated to drive the demand for
radiopharmaceuticals.
The
diagnostics when combined with nuclear medicine improve on accuracy. The
accuracy in the diagnosis has a direct impact on the decision-making and
treatment monitoring process. Adoption of PET as a diagnostic tool is rapidly
increasing since it has high accuracy over other diagnostic techniques.
Browse full
research report on Nuclear Medicine Market: www.grandviewresearch.com/industry-analysis/nuclear-medicines-market
Further key findings from the study suggest:
- The product segments of nuclear medicine are
divided into diagnostic and therapeutic. Diagnostic products held
commanding share in 2015, this can be attributed to the advancements in
scanning technologies.
- Therapeutic products such as Alpha Emitters,
Beta Emitters and Brachytherapy are anticipated to exhibit lucrative
growth.
- The key diagnostic application areas of nuclear
medicine formed the largest market in 2015. These applications are in
cardiology, neurology, oncology, and thyroid.
- North America owing to well-planned policies,
reimbursement structure, high healthcare spending and increasing awareness
dominated global nuclear medicine market in 2015.
- Asia Pacific is expected to witness lucrative
growth in coming eight years. Increasing per capita income and reform in
policies is favoring market players in terms of ease of doing business.
- The players in the nuclear medicine industry
include Eckert & Ziegler Group, Mallinckrodt Pharmaceuticals, GE
Healthcare, Jubilant Life Sciences, Bracco Imaging S.p.A, Nordion, Inc.
Browse more
reports of this category by Grand View Research: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the global nuclear medicine market on
the basis of product and region:
Global
Product Outlook (Revenue, USD Million, 2013 - 2024)
- Diagnostics
- SPECT
- TC-99m
- TL-201
- GA-67
- I-123
- Others
- PET
- F-18
- RB-82
- Others
- Therapeutics
- Alpha
Emitters
- RA-223
- Beta
Emitters
- I-131
- Y-90
- SM-153
- Re-186
- Lu-117
- Others
- Brachytherapy
- Cesium-131
- Iodine-125
- Palladium-103
- Iridium-192
- Others
Regional
Outlook (Revenue, USD Million, 2013 - 2024)
- North
America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia
Pacific
- Japan
- China
- Latin
America
- Brazil
- Mexico
- MEA
- South
Africa
Access
Press Release By Grand View Research: www.grandviewresearch.com/press-release/global-nuclear-medicines-market
About Grand
View Research:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
Comments
Post a Comment